Phase I clinical trial and pharmacokinet
โ
Charles L. Vogel; Elizabeth Gorowski; Enrique Davila; Mario Eisenberger; James K
๐
Article
๐
1987
๐
Springer US
๐
English
โ 823 KB
ICRF-187 was given to 62 evaluable patients with advanced solid tumors in a Phase I clinical trial. Weekly infusions were given in dosages ranging from 0.85 g/m2 to 7.42 g/m2 for a total of four weeks with a two week rest period between courses. Dose-limiting hematological toxicity was seen in heavi